Local Benadryl Inventor Gives $1 Million to Benefit Type 2 Diabetes Research

CINCINNATI—A $1 million gift from Ellen and the late George Rieveschl, PhD, will advance type 2 diabetes research at the University of Cincinnati (UC) College of Medicine.

 

The gift will establish the Rieveschl Medicine Fund to support the work of UC family medicine researcher Robert Smith, MD.

 

Smith, professor emeritus and founder of the UC family medicine program, is studying how a single gene in the human body may determine whether a patient with type 2 diabetes will respond favorably to anti-diabetic drugs.

 

“We are focusing on the possibility that some type 2 diabetes patients have variations in their genes that influence the way they respond to treatment,” Smith says. “If we could tell ahead of time what drug will be most effective for a patient due to their genetic makeup, it would be a major step forward for diabetes treatment in doctors’ offices everywhere.”

 

George Rieveschl, who died Sept. 27, 2007, was a long-time supporter of the UC College of Medicine and the university. A vice president emeritus and 1937 alumnus of UC, Rieveschl was best known for discovering the world’s first commercial antihistamine, Benadryl, while a chemistry professor at UC in the 1940s.

 

“Dr. Smith is a very close and dear friend, and George’s personal physician for more than 30 years,” says wife Ellen Rieveschl. “He’s made huge contributions to the field of medicine—and pioneered family medicine training at medical schools here and abroad. We hope our gift will help move his project forward and perhaps provide a model for other applicable research projects.”

 

In 2003, the Rieveschls funded a $300,000 diabetes pilot project based in UC’s three family medicine clinical practices. The new fund will expand Smith’s research into other family medicine practices throughout Greater Cincinnati.

 

“We are most grateful to Ellen and the late George Rieveschl for their wonderful generosity and for their warm friendship over many years,” says Smith. “With their support, we will be able to access more regional data that might eventually translate into doctors making better decisions on how to treat diabetic patients.”

 

Type 2 diabetes occurs when the body does not produce enough—or ignores the absorption of—insulin. Created inside the pancreas, insulin is a hormone that converts sugar, starches and other food into energy needed for the body. The UC Diabetes Center estimates that 200,000 people in Greater Cincinnati will be diagnosed with type 2 diabetes by 2010.

Robert Smith, MD, professor emeritus of family and community medicine.

Robert Smith, MD, professor emeritus of family and community medicine.

Robert Smith, MD, founder of the UC Headache Center

Robert Smith, MD, founder of the UC Headache Center

George Rieveschl, PhD

George Rieveschl, PhD

George and Ellen Rieveschl

George and Ellen Rieveschl

George Rieveschl, PhD, discovered Benadryl while serving as a chemical engineering professor at UC. The drug became the first FDA-approved prescription antihistamine.

George Rieveschl, PhD, discovered Benadryl while serving as a chemical engineering professor at UC. The drug became the first FDA-approved prescription antihistamine.

Related Stories

1

Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December

December 12, 2025

This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.

2

Ohio nurses weigh in on proposed federal loan rule

December 12, 2025

Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.

3

New combination treatment improves multiple myeloma outcomes

December 11, 2025

The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.